Maki Nakamura/DigitalVision via Getty Images Topline Summary and Update I've been on record as an optimist on the outlook for IDEAYA Biosciences ( IDYA ) starting around last year, due in large part to the untapped potential of their lead compound, darovasertib. As their story continues to evolve, IDYA is continuing to pick up new pipeline projects and push toward a critical readout in what is arg...
Maki Nakamura/DigitalVision via Getty Images Topline Summary and Update I've been on record as an optimist on the outlook for IDEAYA Biosciences ( IDYA ) starting around last year, due in large part to the untapped potential of their lead compound, darovasertib. As their story continues to evolve, IDYA is continuing to pick up new pipeline projects and push toward a critical readout in what is arguably their most important trial to date. Today, I want to digest recent updates on the progress of this trial and other pipeline progress and continue to make the case for optimism in this stock thesis. Pipeline Updates Darovasertib The main pipeline candidate for IDYA remains the protein kinase C inhibitor darovasertib, being explored as an option for patients with uveal melanoma harboring a specific, very common biomarker. As a reminder, uveal melanoma continues to represent an important unmet need, with no traditional chemotherapy, targeted therapy, or immunotherapy so far being able to really touch it. We have tebentafusp for patients of a certain HLA type, but uveal melanoma remains a mostly unmet need in cancer. There are two stories unfolding with darovasertib: as part of a combination in metastatic disease and as a single agent in the pre-surgical setting. For the former, we last saw an update on overall survival at the SMR meeting back in October 2025. Median overall survival for patients in this phase 1/2 study was 21.1 months, comparable to what has been seen with tebentafusp in selected patients and beating historical benchmarks that would be expected in this population. These findings are being further developed in the OptimUM-02 study, which IDYA anticipates will support a filing for approval with the FDA. Topline findings for patients with HLA*A2-negative disease have been guided for the last week of March 2026, but days before this timing, IDYA announced the readout would be delayed until after the database lock in the first half of April, with the data rea...
Dairy Boy founder Paige Lorenze may soon have some more cash to splash on renovations to the $4.7 million mansion she and fiancé Tommy Paul just purchased—after landing a buyer for her Connecticut starter home.
Dairy Boy founder Paige Lorenze may soon have some more cash to splash on renovations to the $4.7 million mansion she and fiancé Tommy Paul just purchased—after landing a buyer for her Connecticut starter home.
(RTTNews) - European stocks soared on Wednesday as a two-week Middle East ceasefire helped ease fears of supply disruptions in oil markets and tempered inflation concerns.
(RTTNews) - European stocks soared on Wednesday as a two-week Middle East ceasefire helped ease fears of supply disruptions in oil markets and tempered inflation concerns.
US President Donald Trump credited Chinese assistance after he agreed to a two-week ceasefire in the war on Iran that includes a resumption of shipping through the vital Strait of Hormuz. “I hear yes,” Trump told Agence France-Presse when asked whether China had helped to get Iran into negotiations, which are due to start in Islamabad, Pakistan on Friday. Iran separately said that it wants China, ...
US President Donald Trump credited Chinese assistance after he agreed to a two-week ceasefire in the war on Iran that includes a resumption of shipping through the vital Strait of Hormuz. “I hear yes,” Trump told Agence France-Presse when asked whether China had helped to get Iran into negotiations, which are due to start in Islamabad, Pakistan on Friday. Iran separately said that it wants China, its biggest trading partner, to be among guarantors of regional peace. The US and Iran both...